These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 12869983

  • 1. Fibrin sealants in supporting surgical techniques: strength in factor XIII.
    Phillips M, Dickneite G, Metzner H.
    Cardiovasc Surg; 2003 Aug; 11 Suppl 1():13-6. PubMed ID: 12869983
    [Abstract] [Full Text] [Related]

  • 2. Fibrin sealants in supporting surgical techniques: The importance of individual components.
    Wozniak G.
    Cardiovasc Surg; 2003 Aug; 11 Suppl 1():17-21. PubMed ID: 12869984
    [Abstract] [Full Text] [Related]

  • 3. Fibrin sealants in clinical practice.
    Albala DM.
    Cardiovasc Surg; 2003 Aug; 11 Suppl 1():5-11. PubMed ID: 12869982
    [Abstract] [Full Text] [Related]

  • 4. Prevention of suture hole bleeding using fibrin sealant: benefits of factor XIII.
    Dickneite G, Metzner H, Nicolay U.
    J Surg Res; 2000 Oct; 93(2):201-5. PubMed ID: 11027461
    [Abstract] [Full Text] [Related]

  • 5. A comparison of fibrin sealants in relation to their in vitro and in vivo properties.
    Dickneite G, Metzner H, Pfeifer T, Kroez M, Witzke G.
    Thromb Res; 2003 Oct; 112(1-2):73-82. PubMed ID: 15013277
    [Abstract] [Full Text] [Related]

  • 6. A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealants.
    Hickerson WL, Nur I, Meidler R.
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):19-23. PubMed ID: 21150581
    [Abstract] [Full Text] [Related]

  • 7. Introduction: Does the evidence justify the routine use of fibrin sealants in cardiovascular surgery?
    Taylor LM.
    Cardiovasc Surg; 2003 Aug; 11 Suppl 1():3-4. PubMed ID: 12869981
    [No Abstract] [Full Text] [Related]

  • 8. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
    Reed GL, Matsueda GR, Haber E.
    Thromb Haemost; 1992 Sep 07; 68(3):315-20. PubMed ID: 1279832
    [Abstract] [Full Text] [Related]

  • 9. [From fibrinogen to fibrin and its dissolution].
    Juhan-Vague I, Hans M.
    Bull Acad Natl Med; 2003 Sep 07; 187(1):69-82; discussion 83-4. PubMed ID: 14556455
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of fibrin seal in animal experiments.
    Haverich A, Maatz W, Walterbusch G.
    Thorac Cardiovasc Surg; 1982 Aug 07; 30(4):215-22. PubMed ID: 6182630
    [Abstract] [Full Text] [Related]

  • 11. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J, Kimura S, Aoki N.
    J Clin Invest; 1986 Mar 07; 77(3):1006-13. PubMed ID: 2419360
    [Abstract] [Full Text] [Related]

  • 12. Factor XIII, fibrin and collagen.
    Duckert F, Nyman D.
    Suppl Thromb Haemost; 1978 Mar 07; 63():391-6. PubMed ID: 262335
    [Abstract] [Full Text] [Related]

  • 13. Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilization.
    Devine DV, Bishop PD.
    Semin Thromb Hemost; 1996 Mar 07; 22(5):409-13. PubMed ID: 8989824
    [Abstract] [Full Text] [Related]

  • 14. Thromboelastograph assay for measuring the mechanical strength of fibrin sealant clots.
    Glidden PF, Malaska C, Herring SW.
    Clin Appl Thromb Hemost; 2000 Oct 07; 6(4):226-33. PubMed ID: 11030529
    [Abstract] [Full Text] [Related]

  • 15. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions.
    Dickneite G, Herwald H, Korte W, Allanore Y, Denton CP, Matucci Cerinic M.
    Thromb Haemost; 2015 Apr 07; 113(4):686-97. PubMed ID: 25652913
    [Abstract] [Full Text] [Related]

  • 16. Effect of fibrin sealant composition on human neutrophil chemotaxis.
    Hanson AJ, Quinn MT.
    J Biomed Mater Res; 2002 Sep 05; 61(3):474-81. PubMed ID: 12115473
    [Abstract] [Full Text] [Related]

  • 17. Biochemical characterization of autologous fibrin sealants produced by CryoSeal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/Tisseel.
    Buchta C, Hedrich HC, Macher M, Höcker P, Redl H.
    Biomaterials; 2005 Nov 05; 26(31):6233-41. PubMed ID: 15921738
    [Abstract] [Full Text] [Related]

  • 18. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
    van Giezen JJ, Minkema J, Bouma BN, Jansen JW.
    Blood Coagul Fibrinolysis; 1993 Dec 05; 4(6):869-75. PubMed ID: 7511944
    [Abstract] [Full Text] [Related]

  • 19. Expression of functional human coagulation factor XIII A-domain in plant cell suspensions and whole plants.
    Gao J, Hooker BS, Anderson DB.
    Protein Expr Purif; 2004 Sep 05; 37(1):89-96. PubMed ID: 15294285
    [Abstract] [Full Text] [Related]

  • 20. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
    Reed GL, Matsueda GR, Haber E.
    Trans Assoc Am Physicians; 1991 Sep 05; 104():21-8. PubMed ID: 1845147
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.